FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new way of treating the most common form of lung
cancer. The investigators are testing a combination of radiotherapy with two new forms of
immunotherapy. This study is testing the safety and effectiveness of this treatment approach
as compared to standard treatment options.